RESUMEN
BACKGROUND: If complement (C) activation is prevented or the host is C depleted, discordant vascularized xenografts undergo delayed xenograft rejection (DXR), characterized by graft infiltration by macrophages (MO) and natural killer (NK) cells, endothelial cell activation, and widespread fibrin deposition. Given a lack of effect of T cell-directed therapies on development of DXR, we evaluated two novel agents, 15-deoxyspergualin (DSG) and leflunomide (LEF), with reported anti-B-cell and/or anti-MO actions. METHODS: DSG and LEF were administered to C-depleted, splenectomized rat recipients of guinea pig cardiac xenografts, and their effects on graft survival and production of anti-guinea pig antibodies were determined. Serial intragraft events were studied by immunohistology using monoclonal antibodies to rat leukocytes, cytokines, and novel proteins, including rat MO lectin, which in other systems is important to MO binding, activation, and target cell killing. RESULTS: Median graft survival was 62 hr in cobra venom factor (CVF)-treated controls versus 108 hr (DSG), 129 hr (LEF), and 120 hr (DSG and LEF; all groups P<0.01 vs. CVF alone). LEF and DSG each decreased (immunoglobulin M [IgM]) or abrogated (IgG) posttransplant production of anti-guinea pig antibodies. Immunohistologic studies showed that each agent also inhibited graft infiltration by NK and T cells, and expression of various cytokines, including the chemokine monocyte chemoattractant protein-1 (MCP-1), but did not affect the tempo or extent of MO infiltration. Consistent with this, the rapid induction of MO lectin postxenografting, and induction of MO lectin by rat MO exposed to guinea pig cells in vitro, were unaffected by therapy with DSG and/or LEF. CONCLUSIONS: LEF or DSG along with CVF can result in the longest prolongation of xenograft survival yet reported in this model, in conjunction with a dampening of host mononuclear cell responses, including suppression of B cell activation. However, the persistent influx of MO in this model, despite lack of C-, Fc receptor- or apparent chemokine-dependent mechanisms, suggests the presence of additional mechanisms for cell recruitment and activation. It was of importance that, in this regard, although MO depletion is technically difficult and can lead to undesired effects, the demonstration of rapid MO lectin induction postxenografting indicates opportunities for blockade of MO recruitment and functions during DXR by use of anti-MO lectin monoclonal antibodies or administration of competing sugars.
Asunto(s)
Guanidinas/farmacología , Trasplante de Corazón/inmunología , Inmunosupresores/farmacología , Isoxazoles/farmacología , Trasplante Heterólogo/inmunología , Animales , Anticuerpos Antiidiotipos/sangre , Anticuerpos Monoclonales/inmunología , Formación de Anticuerpos , Linfocitos B/efectos de los fármacos , Linfocitos B/inmunología , Quimiocina CCL2/biosíntesis , Quimiocinas/farmacología , Proteínas del Sistema Complemento/inmunología , Rechazo de Injerto/prevención & control , Supervivencia de Injerto/fisiología , Guanidinas/uso terapéutico , Cobayas , Inmunoglobulina M/inmunología , Inmunosupresores/uso terapéutico , Isoxazoles/uso terapéutico , Lectinas/biosíntesis , Lectinas/inmunología , Leflunamida , Activación de Macrófagos/efectos de los fármacos , Macrófagos/química , Macrófagos/fisiología , Masculino , Ratas , Ratas Endogámicas BN , Ratas Endogámicas Lew , Ratas Sprague-Dawley , Trasplante Homólogo/inmunologíaAsunto(s)
Formación de Anticuerpos , Transfusión Sanguínea , Rechazo de Injerto/inmunología , Trasplante de Corazón/inmunología , Trasplante Heterólogo/inmunología , Enfermedad Aguda , Animales , Anticuerpos Monoclonales/uso terapéutico , Cricetinae , Rechazo de Injerto/prevención & control , Inmunoglobulina G/biosíntesis , Inmunoglobulina M/sangre , Ganglios Linfáticos/inmunología , Masculino , Mesocricetus , Ratas , Ratas Endogámicas LewRESUMEN
(LEW x BN)F1 cardiac allografts are rejected within 36 hr in LEW rats presensitized with BN skin grafts 7 days earlier (acute rejection occurs within 8 days). We have previously described the effects of individual CD4 (BWH-4), CD25 (IL-2R, ART-18) mAbs, and CsA therapeutic regimens upon cardiac allograft survival in sensitized hosts. The present studies were designed to probe an adjunctive use of ART-18 or CsA upon BWH-4-mediated suppression of accelerated graft injury. Sequential therapy with BWH-4 and ART-18 in the sensitization phase (days -7 to -1) and effector phase (from day 0, the day of cardiac transplant), respectively, prolonged graft survival additively to c. 22 days. Treatment with BWH-4 markedly diminished host humoral response against ART-18 preparation. BWH-4 given in concert with subtherapeutic dose of CsA produced graft survival comparable to that induced by mAb alone (c. 13 days) with concomitant decreased host anti-BWH-4 response. None of the combined regimens affected the frequency of circulating CD4+ cells, as compared with that exerted by BWH-4 monotherapy. Thus this study defines principles and some mechanistic aspects of optimal immunosuppressive strategies potentiating the effects of CD4-targeted therapy.
Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Trasplante de Corazón/inmunología , Animales , Anticuerpos Antiidiotipos/biosíntesis , Anticuerpos Monoclonales/uso terapéutico , Ciclosporina/administración & dosificación , Rechazo de Injerto , Inmunización , Terapia de Inmunosupresión/métodos , Depleción Linfocítica , Ratas , Ratas Endogámicas BN , Ratas Endogámicas Lew , Receptores de Interleucina-2/inmunología , Trasplante de Piel/inmunologíaRESUMEN
CD4 monoclonal antibody therapy prolongs allograft survival in a variety of experimental models and is currently undergoing clinical trials, though surprisingly little is known about the effects of CD4 mAb therapy on intragraft effector mechanisms that mediate rejection. We previously reported the significantly improved survival of (LEWxBN)F1 cardiac allografts in LEW rats treated for 10 days with the new CD4 mAb, BWH-4, at a dose of 700 micrograms/day, i.v., starting at the time of engraftment. Thus, CD4-treated rats showed prolongation of allograft survival to a median of 37 days (range 22 to greater than 100 days) post-Tx, compared with rejection at 7 days in untreated controls. We now report the results of detailed immunohistologic studies of allografts collected from these rats. Comparison of acutely rejecting allografts in untreated rats with well-functioning allografts collected at day 7 post-Tx from CD4-treated rats showed that CD4 mAb: (1) significantly reduced mononuclear cell infiltration, interstitial edema, hemorrhage formation and vascular and extravascular thrombosis; (2) inhibited mononuclear cell induction of receptors for IL-2 and transferrin, and upregulation of class II antigens and ICAM-1 on leukocytes and endothelial cells; (3) suppressed intragraft mononuclear cell and/or endothelial production of the cytokines IL-1, IL-2, IL-6, IFN-gamma, and TNF; and (4) blocked upregulation of endothelial tissue factor and downregulation of thrombomodulin, and consequently inhibited fibrin deposition. Studies of allografts from CD4-treated rats collected at day 30 post-Tx, prior to clinical rejection, showed a resurgence of CD4+ cells within allografts and a dense cellular immune response. We conclude that short-term CD4 mAb therapy has potent and extensive inhibitory effects on cytokine-related mononuclear cell and endothelial activation in vivo, blocking multiple afferent and efferent steps of the alloresponse.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Antígenos CD4/inmunología , Citocinas/metabolismo , Endotelio Vascular/fisiología , Trasplante de Corazón/inmunología , Monocitos/metabolismo , Animales , Rechazo de Injerto/fisiología , Supervivencia de Injerto/efectos de los fármacos , Trasplante de Corazón/patología , Masculino , Ratas , Ratas Endogámicas BN , Ratas Endogámicas Lew , Trasplante HomólogoAsunto(s)
Antígenos/inmunología , Linfocitos T CD4-Positivos/inmunología , Supervivencia de Injerto , Trasplante de Corazón , Terapia de Inmunosupresión/métodos , Animales , Anticuerpos Monoclonales/uso terapéutico , Antígenos de Diferenciación de Linfocitos T/fisiología , Complejo CD3 , Antígenos CD4/fisiología , Masculino , Ratas , Ratas Endogámicas Lew , Receptores de Antígenos de Linfocitos T/fisiología , Trasplante HomólogoRESUMEN
We studied the effects and mechanism of action of BWH-4, an IgG2a mouse antirat CD4 monoclonal antibody that recognizes a distinct epitope on the CD4 molecule, in LEW recipients of (LEW x BN)F1 vascularized heterotopic cardiac allografts. Ten animals received daily injections of 700 micrograms BWH-4 for ten days after engraftment. Median actuarial allograft survival was 37 days for the treated animals compared with 7.5 days for controls (n = 6). There was depletion of peripheral blood CD4+ lymphocytes to 4 +/- 1% one week posttransplant (normal = 48 +/- 4%, n = 6). Six additional animals were treated with a lower dose (100 micrograms) of BWH-4 daily for ten days. Median actuarial allograft survival was 10 days and the circulating CD4+ cells decreased to 30 +/- 6% at one week posttransplant. All six low-dose-treated animals mounted an anti-BN alloantibody response by 3 weeks, while only one of the ten high-dose-treated animals had positive alloantibodies two weeks posttransplant. Lymphocyte-mediated cytotoxicity against donor lymphoblasts was completely abolished in the high-dose-treated animals when compared with acutely rejecting controls. We also used low-dose (100 micrograms) BWH-4 to pretreat eleven experimental animals for 7 days prior to engraftment. The circulating CD4+ cells decreased to only 12 +/- 2% on the day of transplantation and 26 +/- 9% one week posttransplant. However, six (55%) pretreated animals survived more than 55 days. There was a 66% decrease in lymphocyte-mediated cytotoxicity against donor lymphoblasts when compared with acutely rejecting controls. We conclude that the anti-CD4 mAb, BWH-4, prevents acute rejection of vascularized heterotopic rat cardiac allografts; this effect is mediated by depletion of the CD4+ T cell subset, suppression of alloantibody production, and inhibition of lymphocyte-mediated cytotoxicity.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Antígenos CD4/inmunología , Linfocitos T CD4-Positivos/inmunología , Trasplante de Corazón/inmunología , Animales , Anticuerpos Antiidiotipos/biosíntesis , Epítopos , Supervivencia de Injerto , Antígenos de Histocompatibilidad/inmunología , Isoanticuerpos/análisis , Ratas , Ratas Endogámicas , Análisis de Supervivencia , Trasplante HeterotópicoAsunto(s)
Anticuerpos Monoclonales/uso terapéutico , Antígenos CD4/inmunología , Rechazo de Injerto , Supervivencia de Injerto , Trasplante de Corazón/inmunología , Terapia de Inmunosupresión , Animales , Cruzamientos Genéticos , Ciclosporinas/uso terapéutico , Masculino , Ratas , Ratas Endogámicas BN , Ratas Endogámicas Lew , Trasplante HomólogoAsunto(s)
Anticuerpos Monoclonales/uso terapéutico , Supervivencia de Injerto , Enfermedad Injerto contra Huésped/prevención & control , Intestino Delgado/trasplante , Depleción Linfocítica , Subgrupos de Linfocitos T/inmunología , Animales , Citometría de Flujo , Ganglios Linfáticos/inmunología , Masculino , Músculo Liso/trasplante , Ratas , Ratas Endogámicas Lew , Ratas Endogámicas , Receptores de Antígenos de Linfocitos T/inmunologíaRESUMEN
Although CD4-targeted therapy markedly prolongs survival of organ allografts in naive rodents, its effects in primed hosts have not been studied. In our model of accelerated rejection (ACCR) of cardiac Tx in rats, treatment with BWH-4, a CD4 mAb (IgG2a), in the sensitization (between skin and heart Tx) but not in the effector (after cardiac Tx) phase, abrogated fulminant less than 36 hr rejection response and prolonged Tx survival to ca. 11 days. This effect correlated with decreased frequency of circulating CD4+ cells, but it did not depend upon their total depletion. It was also related to BWH-4 mAb-mediated elimination/depression of strong anti-donor humoral responses and cellular responses as determined by lymphocyte-mediated cytotoxicity and mixed lymphocyte reaction and mounted otherwise at the time of engraftment by untreated sensitized hosts. Immunoperoxidase studies of cardiac Tx from BWH-4-conditioned recipients revealed reduced T and B cell activities, reflected in abolition/reduction in deposition of humoral mediators, infiltrating cells, intra-Tx elaboration of interleukin-2 and interferon-gamma, and cell activation. This first report of the successful use of CD4 mAb in sensitized recipients of vascularized organ Tx, stresses the role of CD4+ cells as potential targets for immunosuppression in the sensitization phase of accelerated Tx injury. The beneficial therapeutic effect, probably due to both depletion and functional inhibition of CD4+ T cells, has been achieved by using relatively low doses of BWH-4 mAb.
Asunto(s)
Antígenos CD4/fisiología , Rechazo de Injerto , Linfocitos T/fisiología , Animales , Anticuerpos Monoclonales/inmunología , Formación de Anticuerpos , Antígenos de Superficie/análisis , Antígenos CD4/análisis , Supervivencia de Injerto , Trasplante de Corazón , Prueba de Cultivo Mixto de Linfocitos , Masculino , Ratas , Ratas EndogámicasRESUMEN
LEW strain rats received BN strain renal allografts and were treated with daily injections of 100 micrograms BWH-4, a new IgG2a mouse anti-rat CD4 monoclonal antibody, intravenously for 5 to 10 days. These animals had a median actuarial survival of 28 days. Control animals rejected their grafts and died of uremia between day 6 and 8 post transplant. Animals treated with BWH-4 did not suffer acute graft loss and had stable renal function throughout the follow-up period of 5 weeks. Peripheral blood, lymph node, and splenic lymphocytes showed 60-80% decrease in the CD4+ subset which normalized by 4 weeks after transplantation. There was depressed proliferative response of lymph node cells to alloantigen and mitogen which persisted up to 4 weeks after cessation of therapy. Treated animals produced anti-BN antibodies as well as antibodies to the infused BWH-4. There was no correlation, however, between these humoral responses and allograft function. We conclude that low-dose monotherapy with the BWH-4 anti-CD4 monoclonal antibody effects cellular hyporesponsiveness, prevents acute renal allograft rejection, and prolongs survival.